Brokers Set Expectations for Omega Therapeutics, Inc.'s Q3 2025 Earnings (NASDAQ:OMGA)

Omega Therapeutics, Inc. (NASDAQ:OMGA - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Omega Therapeutics in a report issued on Monday, May 13th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Omega Therapeutics' current full-year earnings is ($1.30) per share. HC Wainwright also issued estimates for Omega Therapeutics' Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.19) EPS.

A number of other equities research analysts have also issued reports on OMGA. Piper Sandler reaffirmed an "overweight" rating and set a $9.00 target price (down previously from $10.00) on shares of Omega Therapeutics in a report on Wednesday, April 3rd. Chardan Capital reissued a "buy" rating and issued a $7.00 price objective on shares of Omega Therapeutics in a report on Tuesday, May 7th. Finally, Wedbush reissued an "outperform" rating and issued a $12.00 price objective on shares of Omega Therapeutics in a report on Monday, May 6th.

Omega Therapeutics Price Performance

Shares of Omega Therapeutics stock traded up $0.01 during trading hours on Tuesday, reaching $2.36. 426,857 shares of the company's stock were exchanged, compared to its average volume of 1,590,475. Omega Therapeutics has a 1 year low of $1.30 and a 1 year high of $10.09. The company has a market capitalization of $130.15 million, a P/E ratio of -1.41 and a beta of 1.99. The business has a fifty day moving average of $2.99 and a two-hundred day moving average of $3.00. The company has a quick ratio of 2.87, a current ratio of 2.87 and a debt-to-equity ratio of 0.34.

Omega Therapeutics (NASDAQ:OMGA - Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.09. The company had revenue of $0.99 million during the quarter, compared to analyst estimates of $0.93 million. Omega Therapeutics had a negative net margin of 1,868.35% and a negative return on equity of 136.04%.

Institutional Trading of Omega Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in OMGA. 683 Capital Management LLC boosted its holdings in Omega Therapeutics by 7.0% during the third quarter. 683 Capital Management LLC now owns 508,242 shares of the company's stock worth $1,093,000 after buying an additional 33,242 shares in the last quarter. Murphy Pohlad Asset Management LLC purchased a new stake in Omega Therapeutics in the 4th quarter valued at approximately $50,000. Finally, Etfidea LLC purchased a new stake in Omega Therapeutics in the 4th quarter valued at approximately $39,000. Hedge funds and other institutional investors own 97.47% of the company's stock.

Omega Therapeutics Company Profile

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.